SPC changes
Dovobet ointment
The summary of product characteristics for Dovobet (calcipotriol and
betamethasone dipropionate; Leo Pharma) now states that after the recommended
treatment period of four weeks repeated treatment with Dovobet can be
initiated under medical supervision. See SPC.
Erbitux
The summary of product characteristics for Erbitux (cetuximab; Merck)
has been updated to include an additional indication for the treatment,
in combination with radiation therapy, of patients with locally advanced
squamous cell cancer of the head and neck. See SPC.
Back to Top
|